This study investigates advanced pancreatic cancer with elevated levels of CA19-9.
The study evaluates how well chemotherapy combined with radiotherapy works for patients with this condition. It looks at safety and effectiveness, including measures like progression-free survival and overall survival.
- Who can participate: Adults aged 18 to 80 with advanced pancreatic adenocarcinoma and elevated CA19-9 levels can participate. Participants must not have had previous radiotherapy or be refractory to chemotherapy.
- Study details: Participants will receive chemotherapy and radiotherapy.